Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8044343 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL20745515 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL9218563 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL6545054 | 1.00 | CD274 (0.50) | CD274GRM6MAOAMAOBMAPT | |
| Hydrochloric Acid SCHEMBL2495103 | 0.98 | CD274 (0.49) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL27508562 | 0.88 | MAOA (0.62) | GRM6MAOAMAOBMAPTKDM4E | |
| SCHEMBL1162855 | 0.88 | MAOA (0.62) | GRM6MAOAMAOBMAPTKDM4E | |
| SCHEMBL18347538 | 0.86 | MAPT (0.55) | CD274GRM6MAOAMAOBMAPT | |
| SCHEMBL24938939 | 0.85 | CYP3A4 (0.50) | MAOAMAOBMAPTKDM4E | |
| SCHEMBL4249938 | 0.85 | CYP3A4 (0.50) | MAOAMAOBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4110394-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | Pfizer Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022152852-A1 | ANTAGONISTS OF MRGX2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-07-21 | — | — | WO | disclosed |
| US-11065249-B2 | Diacylglycerol acyl transferase 2 inhibitor | PFIZER INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210100798-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | US | disclosed |
| WO-2021064590-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | PFIZER INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2018165611-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-13 | — | — | WO | disclosed |
| CN-106573031-A | Bi-terminal pegylated integrin-binding peptides and methods of use thereof | 加利福尼亚大学董事会 | 2017-04-19 | — | — | CN | disclosed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20040115240-A1 | Composite for attaching, growing and/or repairing of living tissues and use of said composite | VIVOXID OY (FI) | 2004-06-17 | — | — | US | disclosed |
| EP-1377325-A1 | COMPOSITE FOR ATTACHING, GROWING AND/OR REPAIRING OF LIVING TISSUES AND USE OF SAID COMPOSITE | Vivoxid Oy (FI) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002074356-A1 | COMPOSITE FOR ATTACHING, GROWING AND/OR REPAIRING OF LIVING TISSUES AND USE OF SAID COMPOSITE | VIVOXID OY (FI) | 2002-09-26 | — | — | WO | disclosed |
| US-5608056-A | Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0636133-A1 | SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021186-A1 | SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-28 | — | — | WO | disclosed |
| EP-0082088-A1 | Derivatives of amino acids and their therapeutic use | Roques, Bernard (FR) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065249-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | CD274 4832/4885GRM6 3009/4885MAOA 2466/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | CD274 3769/4885GRM6 2068/4885MAOA 3265/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CD274 3769/4885GRM6 2068/4885MAOA 3265/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | CD274 4818/4885GRM6 3927/4885MAOA 1212/4885 |
| US-20210100798-A1 | DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR | DGAT2, DGAT1, ACAT2 | CD274 4825/4885GRM6 3011/4885MAOA 2462/4885 |
| US-11471458-B2 | Diacylglycerol acyl transferase 2 inhibitor | DGAT2, DGAT1, ACAT2 | CD274 4832/4885GRM6 3009/4885MAOA 2466/4885 |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | ABCB11, ABCB1, ABCG2 | CD274 4734/4885GRM6 3772/4885MAOA 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.